aTyr Pharma Reports $19.5 Million Net Loss in Q2 2025, No Revenue Generated

aTyr Pharma, Inc. reported its financial results for the second quarter of 2025, revealing a consolidated net loss of $19.5 million, compared to a net loss of $16.3 million for the same period in 2024. The company did not generate any revenue during the quarter, maintaining a total revenue of $0 for the first half of 2025, a significant decrease from $235,000 in the prior year. Operating expenses increased to $20.3 million for the three months ended June 30, 2025, up from $17.3 million in the same quarter of 2024, primarily driven by higher research and development costs associated with the ongoing development of its lead therapeutic candidate, efzofitimod.

In terms of financial position, aTyr Pharma reported total assets of $101.5 million as of June 30, 2025, an increase from $96.8 million at the end of 2024. The company’s cash and cash equivalents rose to $17.2 million, up from $11.1 million at the end of the previous fiscal year. The increase in cash was bolstered by net proceeds of approximately $36.7 million from the issuance of common stock through its at-the-market offering program during the first half of 2025. The company’s accumulated deficit also grew to $566.5 million, reflecting ongoing investment in its clinical programs.

Operationally, aTyr Pharma has focused on advancing efzofitimod, which is in clinical development for interstitial lung disease (ILD). The company has completed enrollment for its pivotal Phase 3 EFZO-FIT study, with the last patient visit concluded in July 2025. Topline data from this study is expected in mid-September 2025. Additionally, the company has initiated an Individual Patient Expanded Access Program for efzofitimod, allowing patients who completed the Phase 3 study to receive treatment outside of the clinical trial.

The company’s workforce has also expanded, with the number of common shares outstanding increasing to 92.9 million as of June 30, 2025, up from 84.0 million at the end of 2024. This increase reflects the issuance of shares through stock options and the at-the-market offering program. aTyr Pharma continues to explore additional funding avenues to support its operations, including potential collaborations and licensing arrangements, as it anticipates significant commercialization expenses if it secures regulatory approval for efzofitimod.

Looking ahead, aTyr Pharma expects to continue incurring losses as it advances its clinical programs and prepares for potential commercialization. The company believes its existing cash and investments will be sufficient to meet its operational needs for at least the next year, but it acknowledges the necessity of raising additional capital to fund ongoing and future development activities. The company remains focused on its strategic goals, including the successful development of efzofitimod and the exploration of new therapeutic candidates derived from its tRNA synthetase biology platform.